SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Keryx Biopharmaceuticals, Inc (KERX)

KERX RSS Feed
Add KERX Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 9/6/2017 9:48:47 AM - Followers: 135 - Board type: Free - Posts Today: 0

 

 

 

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both multiple myeloma and refractory advanced colorectal cancer, and in Phase 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing ZerenexTM (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of ZerenexTM in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is pending commencement under an SPA agreement with the FDA. Keryx also actively engages in business development activities that include seeking strategic relationships for its product candidates, as well as evaluating compounds and companies for in-licensing or acquisition.

Keryx is headquartered in New York City.

Keryx Biopharmaceuticals is traded on the Nasdaq Stock Market under the symbol "KERX."





Corporate Headquarters

 

Keryx Biopharmaceuticals, Inc.
750 Lexington Ave. - 20th Floor
New York, NY 10022
Phone: 1-212-531-5965
Fax: 1-212-531-5961
Contact Email
Investor Relations IR@keryx.com
Business Development BusDev@keryx.com
Clinical Trials ClinicalTrials@keryx.com
Employment Opportunities

Company Website
jobs@keryx.com

http://www.keryx.com/



 

Product candidate Target indication Development status
     
ZerenexTM (ferric citrate) Hyperphosphatemia in patients with end-stage renal disease U.S. Phase 3 program ongoing under SPA; 
Japan Phase 3 program ongoing by sublicensee (JT and Torii)

 

Recent News:

http://ih.advfn.com/p.php?pid=news&symbol=N%5EKERX

http://www.otcmarkets.com/stock/KERX/news  

http://investors.keryx.com/phoenix.zhtml?c=122201&p=irol-news&nyo=0

Charts:

Gallery views:

http://stockcharts.com/freecharts/gallery.html?kerx


 

                KERX - Daily Candlesticks  


Analyst's estimates and ratings: 
http://investing.money.msn.com/investments/analyst-ratings/?symbol=kerx

http://www.marketwatch.com/investing/stock/KERX/analystestimates?subview=snapshot&pg=analyst

 

The most recent Quarterly (10-Q)
 
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8450533

Do your own DD and trade smart.


 
 
  
SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
KERX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
KERX News: Current Report Filing (8-k) 09/13/2017 04:18:36 PM
KERX News: Keryx Biopharmaceuticals Announces Changes to its Board of Directors 09/13/2017 04:10:00 PM
KERX News: Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in September 2017 09/05/2017 08:01:00 AM
KERX News: Current Report Filing (8-k) 09/01/2017 04:32:07 PM
KERX News: Keryx Biopharmaceuticals to Webcast its Presentation at Canaccord Genuity’s 37th Annual Growth Conference on August 9, 2017... 08/04/2017 08:31:00 AM
PostSubject
#3046   kerx gonna be a big gainer! $$$ harry crumb 09/06/17 09:48:47 AM
#3045   over 8 an then profit taking an shorting, harry crumb 09/05/17 05:15:19 PM
#3044   71% institutional ownership people, that is fact, look harry crumb 09/01/17 02:59:17 PM
#3043   Nice day today for sure! Hope the momentum fsulevine 09/01/17 02:47:32 PM
#3042   started buying more in low 6's, 10$ is harry crumb 08/30/17 08:50:51 AM
#3041   1 yr chart is looking good folks for harry crumb 08/26/17 10:41:45 PM
#3040   Out dave2808 08/25/17 11:13:06 AM
#3039   Breaking 7.00 tomorrow dave2808 08/23/17 07:08:26 PM
#3038   yup, agree. adding more here harry crumb 08/18/17 10:47:02 PM
#3037   Time to reload 6.55 dave2808 08/18/17 10:07:02 AM
#3036   Out today at 6.97 dave2808 08/16/17 11:59:05 AM
#3035   I'm back in at 6.46 dave2808 08/09/17 04:04:08 PM
#3034   FDA decision: Nov 2017 H2R 08/09/17 12:04:40 PM
#3033   Okay. I appreciate the information! One question... what fsulevine 07/28/17 06:39:15 AM
#3032   fs from the Co Whalatane 07/27/17 05:12:05 PM
#3031   Okay, interesting. But am I confused here? I fsulevine 07/27/17 04:18:04 PM
#3030   fs ...well after a little research Whalatane 07/27/17 03:14:49 PM
#3029   FS KERX's phase 3 Whalatane 07/27/17 12:01:10 PM
#3028   FS yes .. I'm reading up on Whalatane 07/27/17 11:48:26 AM
#3027   It is approved currently for patients on dialysis, fsulevine 07/27/17 11:41:30 AM
#3026   FS Thx for clarifying that . Whalatane 07/27/17 11:38:01 AM
#3025   Okay. But Auryxia is a phosphate binder for fsulevine 07/27/17 11:11:59 AM
#3024   Fs I believe you asked me about Whalatane 07/27/17 11:07:07 AM
#3023   load up, next level is 10pps! $$$ harry crumb 07/27/17 09:51:36 AM
#3022   Good earnings I think, once you take out fsulevine 07/27/17 08:07:18 AM
#3021   new 52 week high! go kerx!! $$$$ harry crumb 07/12/17 10:43:54 AM
#3020   consolidation here is good! harry crumb 07/10/17 09:46:26 PM
#3019   10$ next! harry crumb 07/07/17 01:52:16 PM
#3018   Oh btw I'm a long here and believe Radtech 07/05/17 10:02:55 PM
#3017   Oh you mean those Form 4s and the Radtech 07/05/17 09:59:17 PM
#3016   read the news from june! harry crumb 07/05/17 04:52:40 PM
#3015   Insider buys??? Link? Radtech 07/04/17 05:55:42 PM
#3014   insider buys! $$$ harry crumb 07/04/17 10:56:24 AM
#3013   nice..good for you. we bought 95k more harry crumb 07/02/17 12:39:03 AM
#3012   Hope so! That said, I plan to sell fsulevine 06/30/17 06:27:29 PM
#3011   gonna propel the stock to 11 area harry crumb 06/30/17 05:39:29 PM
#3010   SPHS upcoming soon for patient data.. check out . nymostwanted 06/28/17 04:35:12 PM
#3009   go kerx harry crumb 06/26/17 01:40:21 PM
#3008   told everyone! harry crumb 06/23/17 12:26:08 PM
#3007   going back up people harry crumb 06/18/17 01:10:46 PM
#3006   we added 80k to position, buyout material folks, harry crumb 06/16/17 01:58:14 PM
#3005   go to stocktwits and read message board dave2808 06/16/17 11:17:20 AM
#3004   Anybody know why the stock has been crushed fsulevine 06/16/17 10:37:37 AM
#3003   12$ pps isnt to far away harry crumb 05/05/17 06:46:42 PM
#3002   Cool... thank you for the info! Been a fsulevine 05/05/17 07:59:21 AM
#3001   Keryx Announces that Auryxia® (Ferric Citrate) is Now dave2808 05/05/17 07:05:49 AM
#3000   Keryx Announces that Auryxia® (Ferric Citrate) is Now dave2808 05/05/17 07:03:19 AM
#2999   I have been busy most of the week... fsulevine 05/05/17 06:44:11 AM
#2998   $11.8 million in first quarter 2017 total H2R 05/04/17 10:06:44 AM
#2997   Also hearing their in line to beat earnings dave2808 05/01/17 08:37:59 AM
PostSubject